Article Text

Download PDFPDF
Correspondence
Authors’ response to Walker et al.
  1. D P Tashkin1,
  2. N Metzdorf2,
  3. C Hallmann2,
  4. I Leimer2,
  5. T Lee3,
  6. M Decramer4
  1. 1David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
  2. 2Clinical Development & Medical Affairs Ingelheim, Boehringer Ingelheim Pharma GmbH & Co KG, Germany
  3. 3Pfizer Inc., New York, New York, USA
  4. 4Respiratory Division, KU Leuven, Leuven, Belgium
  1. Correspondence to Dr Norbert Metzdorf, TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Strasse 173, D-55216 Ingelheim am Rhein, Germany; norbert.metzdorf{at}boehringer-ingelheim.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The research letter by Walker et al1 questions the generalisability of the results of the 4-year UPLIFT trial comparing tiotropium versus placebo based on potential eligibility for UPLIFT at time of discharge of a COPD patient population in New Zealand hospitalised for an exacerbation. The authors state that 38% of their study population would have been excluded from UPLIFT. The authors' assertion regarding the limited generalisability of UPLIFT's findings to clinical practice is not valid for several reasons.

First, patients hospitalised for COPD exacerbations are not representative of the general COPD population. An epidemiological analysis from The Netherlands2 reported that 2.1% and 4.4% of COPD patients (mean age, 68 years) starting treatment with HandiHaler and Respimat, respectively, had a COPD-related hospitalisation in the year preceding the analysis. Analysis of an elderly Canadian COPD population3 showed that 9.8% were recently hospitalised for acute respiratory conditions. These epidemiological data suggest that the COPD population studied by Walker et al is not representative of the general COPD population. …

View Full Text

Footnotes

  • Contributors DPT contributed to the analysis and interpretation of a post hoc analysis of ‘patients excluded from UPLIFT at baseline’. DPT also conceived, drafted, read and approved the letter. NM contributed to the analysis and interpretation of a post hoc analysis of ‘patients excluded from UPLIFT at baseline’. NM also conceived, drafted, read and approved the letter. NM is the guarantor for the overall content of the letter. CH contributed to the analysis and interpretation of a post hoc analysis of ‘patients excluded from UPLIFT at baseline’. CH also conceived, drafted, read and approved the letter. IL generated new data based on a post hoc analysis of ‘patients excluded from UPLIFT at baseline’. IL also, conceived, drafted, read and approved the letter. TL contributed to the analysis and interpretation of a post hoc analysis of ‘patients excluded from UPLIFT at baseline’. TL also, conceived, drafted, read and approved the letter. MD contributed to the analysis and interpretation of a post hoc analysis of ‘patients excluded from UPLIFT at baseline’. MD also, conceived, drafted, read and approved the letter.

  • Funding This work was sponsored and supported by Boehringer Ingelheim Pharma GmbH & Co KG and Pfizer Inc.

  • Competing interests DPT reports personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, personal fees from Novartis, personal fees from Theravance, personal fees from Dey Laboratories, personal fees from Sunovion, grants from Boehringer Ingelheim, grants from Almirall, grants from AstraZeneca, grants from Dey Laboratories, grants from Merck & Co., grants from Novartis, grants from Pfizer, grants from Sunovion and grants from Forest Laboratories, outside the submitted work. NM reports personal fees from Boehringer Ingelheim as an employee during the conduct of the study; personal fees from Boehringer Ingelheim as an employee, outside the submitted work. CH reports personal fees from Boehringer Ingelheim as an employee during the conduct of the study; personal fees from Boehringer Ingelheim as an employee, outside the submitted work. IL reports personal fees from Boehringer Ingelheim as an employee during the conduct of the study; personal fees from Boehringer Ingelheim as an employee, outside the submitted work. TL reports personal fees from Pfizer Inc. as an employee during the conduct of the study; personal fees from Pfizer Inc. as an employee, outside the submitted work. MD reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Pfizer, personal fees from Dompé, personal fees from GlaxoSmithKline, personal fees from Novartis, personal fees from Nycomed, grants from AstraZeneca, grants from Boehringer Ingelheim/Pfizer, grants from GlaxoSmithKline, outside the submitted work.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles